Latest Period
Q2 2026
Security Snapshot
Immuneering Corp - Class A Stock (IMRX) Institutional Ownership
CUSIP: 45254E107
13F Institutional Holders and Ownership History from Q3 2021 to Q2 2026
Institutions Reporting
112
Shares (Excl. Options)
34,451,907
Price
$4.99
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Class A Stock
- Symbol
- IMRX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 34,451,907
- Total 13F value
- $171,663,708
- Portfolio coverage rank
- 0%
- Share change
- +5,128,946
- Value change
- +$25,531,260
- Number of holders
- 112
- Shares outstanding
- 65,018,433
- SEC-reported price per share
- $4.24
- Insider filing price
- $4.24
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- IMRX - Immuneering Corp - Class A Stock is tracked under CUSIP 45254E107.
- 112 institutions reported positions in Q2 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 95 to 112 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $154,283,703 to $171,663,708.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 112 institutions filings for Q2 2026.
Security key
45254E107
Latest holder period
Q2 2026
13F holders
112
13D/G owners
5
CIK / CUSIP context first
Open Q2 2026 holders
IMRX full holder history
Immuneering Corp SEC filings
Immuneering Corp company facts
Immuneering Corp insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 45254E107:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
IMRX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 14% | $71,526,603 | 8,787,052 | FMR LLC | 30 Sep 2025 | |||
| Zeskind Benjamin J. | 6.6% | -48% | $28,674,370 | +$2,498,025 | 4,357,807 | +9.5% | BENJAMIN J. ZESKIND | 31 Dec 2025 |
| BlackRock, Inc. | 6.7% | $21,737,613 | 4,356,235 | BlackRock, Inc. | 30 Jun 2026 | |||
| HBM Healthcare Investments (Cayman) Ltd. | 5.7% | $29,680,915 | 3,646,304 | HBM Healthcare Investments (Cayman) Ltd. | 26 Sep 2025 | |||
| Empery Asset Management, LP | 5% | -43% | $20,154,805 | -$12,015,476 | 3,250,775 | -37% | Empery Asset Management, LP | 31 Dec 2025 |
As of 30 Jun 2026, 112 institutional investors reported holding 34,451,907 shares of Immuneering Corp - Class A Stock (IMRX). This represents 53% of the company’s total 65,018,433 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
48%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 9,704,610 | +0.07% | 0% | $48,426,004 |
| BlackRock, Inc. | 6.7% | 4,374,020 | +190% | 0% | $21,826,360 |
| Sanofi | 4.2% | 2,708,559 | 0% | 2.5% | $13,515,709 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.5% | 2,286,434 | -0.08% | 0% | $11,409,306 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3% | 1,936,076 | +5.8% | 0% | $9,662,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.1% | 1,370,750 | +115% | 0% | $6,841,807 |
| STATE STREET CORP | 1.5% | 1,001,995 | +273% | 0% | $4,999,955 |
| DCF Advisers, LLC | 1.2% | 790,000 | +458% | 1% | $3,942,100 |
| MARSHALL WACE, LLP | 1.1% | 731,897 | -63% | 0% | $3,652,164 |
| Connor, Clark & Lunn Investment Management Ltd. | 0.92% | 601,255 | +50% | 0.01% | $3,000,262 |
| ALETHEA CAPITAL MANAGEMENT, LLC | 0.73% | 472,935 | +1962% | 0.98% | $2,359,946 |
| Summit Financial, LLC | 0.7% | 452,264 | +20% | 0.02% | $2,256,797 |
| UBS Group AG | 0.69% | 448,857 | +19% | 0% | $2,239,796 |
| Nuveen, LLC | 0.67% | 438,362 | 0% | $2,187,427 | |
| NORTHERN TRUST CORP | 0.67% | 436,992 | +271% | 0% | $2,180,590 |
| LEVIN CAPITAL STRATEGIES, L.P. | 0.64% | 414,000 | +4040% | 0.14% | $2,065,860 |
| CITADEL ADVISORS LLC | 0.59% | 386,411 | -14% | 0% | $1,928,191 |
| VANGUARD FIDUCIARY TRUST CO | 0.55% | 360,764 | +12% | 0% | $1,800,212 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.55% | 359,085 | 0% | $1,791,834 | |
| GSA CAPITAL PARTNERS LLP | 0.53% | 343,303 | +347% | 0.11% | $1,713,000 |
| MILLENNIUM MANAGEMENT LLC | 0.51% | 330,402 | -70% | 0% | $1,648,706 |
| Burkehill Global Management, LP | 0.46% | 300,000 | 0% | 0.05% | $1,497,000 |
| TWO SIGMA INVESTMENTS, LP | 0.44% | 288,420 | +18% | 0% | $1,439,216 |
| Occam Crest Management LP | 0.43% | 278,498 | -49% | 0.62% | $1,129,309 |
| MORGAN STANLEY | 0.35% | 226,491 | -24% | 0% | $1,130,190 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
20
Latest
Q2 2026
Rows shown
1-20 of 20
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 34,451,907 | $171,663,708 | +$25,531,260 | $4.99 | 112 |
| 2026 Q1 | 29,305,817 | $154,283,703 | -$17,093,647 | $5.27 | 95 |
| 2025 Q4 | 31,752,244 | $208,911,171 | +$18,277,430 | $6.58 | 87 |
| 2025 Q3 | 26,061,962 | $182,434,908 | +$152,080,293 | $7.00 | 69 |
| 2025 Q2 | 3,829,641 | $12,906,115 | -$684,732 | $3.37 | 39 |
| 2025 Q1 | 4,498,583 | $6,835,562 | +$160,625 | $1.52 | 34 |
| 2024 Q4 | 4,238,711 | $9,324,244 | -$178,796 | $2.20 | 41 |
| 2024 Q3 | 4,355,017 | $10,869,922 | -$7,529,696 | $2.49 | 38 |
| 2024 Q2 | 9,594,278 | $12,279,759 | -$9,114,134 | $1.28 | 57 |
| 2024 Q1 | 11,871,050 | $34,309,079 | -$12,746,356 | $2.89 | 50 |
| 2023 Q4 | 16,130,676 | $118,561,919 | -$6,044,147 | $7.35 | 52 |
| 2023 Q3 | 16,940,765 | $130,107,793 | -$5,076,687 | $7.68 | 52 |
| 2023 Q2 | 17,269,962 | $175,881,466 | +$55,986,602 | $10.14 | 49 |
| 2023 Q1 | 11,823,558 | $114,882,649 | +$3,734,772 | $9.71 | 34 |
| 2022 Q4 | 11,722,865 | $56,864,840 | -$4,241,513 | $4.85 | 32 |
| 2022 Q3 | 12,063,607 | $172,475,348 | -$5,229,083 | $14.32 | 30 |
| 2022 Q2 | 12,148,741 | $65,706,270 | -$8,960,781 | $5.41 | 33 |
| 2022 Q1 | 13,611,716 | $88,116,760 | -$3,464,272 | $6.47 | 49 |
| 2021 Q4 | 12,489,185 | $199,826,000 | +$5,452,786 | $16.17 | 36 |
| 2021 Q3 | 12,105,226 | $316,421,451 | +$316,421,451 | $26.55 | 38 |